PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1133441
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1133441
Contact us about how to customize the report with add-on data.
According to Stratistics MRC, the Global Pulmonary Function Testing System Market is accounted for $145.34 million in 2022 and is expected to reach $210.88 million by 2028 growing at a CAGR of 6.4% during the forecast period. Pulmonary function testing system is a device that performs various pulmonary function tests such as respiratory mechanics, nitrogen washout, spirometry, lung volumes, vital capacity, plethysmography, and diffusion capacity. There are two types of devices available namely complete, and portable systems. These devices can be utilized to monitor people suffering from severe breathing complaints such as asthma and COPD. The systems assist in diagnosing lung disorders and selecting treatment or therapeutics for lung disorders. PFTs are extremely beneficial in recognizing the preliminary-stage irregularities in asymptomatic patients and in assessing the damage to the lungs before any signs and symptoms develop.
According to the American Cancer Society, in the United States around 228,150 new cases of lung cancer occur in 2019. Additionally, around 142,670 deaths occur from lung cancer (76,650 in men and 66,020 in women). In addition, the growing demand for minimally invasive tests to design an appropriate method of treating lung disease is supplementing the market growth. According to data by the Centers for Disease Control and Prevention (CDC), cigarette smoking is the leading cause of death in the United States. Tobacco consumption kills more than 4,80,000 Americans each year, with more than 41,000 of these deaths due to exposure to secondhand smoke.
Increasing prevalence of respiratory diseases
In recent years, respiratory ailments, such as Chronic Obstructive Pulmonary Disease (COPD), asthma, lung cancer, and occupational lung diseases, have been the leading reasons of fatality across the globe. Furthermore, there is a considerable increase in the incidence of chronic obstructive pulmonary diseases and asthma globally, especially in developing countries. According to the Global Asthma Report 2018, in India, among 1.31 billion people, about 2% of adults and 6% of children have asthma. Such high cases of asthma are expected to increase the adoption of these systems during the forecast timeframe. In COPD and other chronic respiratory diseases, lung capacity is an important parameter. Lung capacity refers to the air volume in lungs at different respiratory cycle phases. The pulmonary function testing systems help to measure different parameters of the lungs with the help of various tests such as spirometry and plethysmography and diagnose COPD and other lung-related disorders. Such a huge occurrence of chronic respiratory diseases necessitating pulmonary function tests and the rising focus of companies to increase their presence in developing countries for these systems are expected to boost the market growth in the coming years.
Risk of cross contamination
Pulmonary function testing represents a potential avenue for the transmission of infection due to the congregation of patients with lung disease and the potential for coughing and droplet formation surrounding pulmonary function test procedures. These systems include mouthpieces, rebreathing valves, and tubings used in the laboratory. Mouthpieces are the most common cause of cross-infection during testing. Factors, such as exposed surface areas, quality of upholstery, general clutter, air conditioning, optimum temperature, and humidity conditions, lead to the cross-infection such as the risk of the development of tuberculosis.
Shift towards portable systems from complete systems
The companies functioning in the global market incessantly emphasize on developments, such as launching portable systems with more parameters and promoting the adoption of these devices in independent clinics. These strategies shifted the espousal of complete to portable systems, thereby spurring the overall market growth. Aspects such as immobile, low cost, and presence of standard parameters, such as lung volumes, diffusion capacity, and spirometry, stimulated the healthcare facilities to shift towards portable systems.
Lack of skilled healthcare professionals in underdeveloped countries
There is a shortage of trained healthcare professionals in developing countries. For example, according to the article published by BMJ Publishing Group Ltd in May 2019, in India, the density of the total health professional is estimated to be 29 per 10,000 populations; however, only 16 per 10,000 is the density of trained workers. In addition, the trained health workforce in India does not meet the minimum threshold of 22.8 skilled workers per 10,000 populations, which is recommended by the World Health Organization (WHO). Such unavailability of a skilled workforce to operate PFT systems associated with these systems are expected to obstruct the market growth during the forecast period.
The COVID-19 epidemic led to abridged demand for pulmonary function testing (PFT) systems during the forecast period, due to the prominent reduction in the implementation of PFT systems during the peak time of COVID-19. Nevertheless, after the easing of lockdown in a few nations, the PFT systems were reinstated in the healthcare units with RT-PCR tests. The government of every nation is procuring and manufacturing more mobile pulmonary function testing devices which are rapid as well as require less human contact. This has surely given a hike to market for pulmonary function testing share.
The portable PFT systems segment is expected to be the largest during the forecast period
The portable PFT systems segment is anticipated to have a lucrative growth, due to the increase in the adoption of portable systems in independent and diagnostics clinics, increasing launches of these products for the diagnosis of asthma and COPD, and rising air pollution.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period, due to increasing espousal of complete systems for diagnosing patients in hospitals and the surging footfalls of COPD and asthma patients in the hospitals.
Region with highest share:
North America is projected to have the largest market share during the forecast period, due to rising technological advancements in diagnostics, well-developed healthcare infrastructure, increasing prevalence of chronic respiratory diseases, the prompt implementation of portable systems and the bolstering usage of these devices in physician groups (clinics) in the region, and rising hospital admissions.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to growing footprints of market players in developing countries of Asia Pacific, growing emphasis on enhancing hospital infrastructure, rising awareness regarding the usage of pulmonary function tests, and increasing demand for pulmonary function testing devices in private hospitals and clinics in the region.
Key players in the market
Some of the key players profiled in the Pulmonary Function Testing System Market include NSPIRE HEALTH INC., Koninklijke Philips N.V., COSMED Srl, Omron Healthcare, Inc., Morgan Scientific Inc., Becton, Dickinson and Company., Schiller AG, PulmOne, Vyaire Medical, Inc, Minato Holdings Inc., MGC Diagnostic Corporation, 3M, Ganshorn Medizin Electronic, Data Sciences International, and Medline Industries.
In September 2020, PulmOne Advanced Medical Devices announced the launch of MiniBox Academy, an innovative, self-paced e-learning training and certification program for MiniBox+ customers. The academy is designed to improve PFT testing expertise, ensure testing consistency, reproducibility, and accuracy and facilitate an outstanding patient experience.
In March 2018, COSMED Srl launched altogether new catalogue of products for monitoring and screening of pulmonary function testing.
In October 2017, Vyaire Medical, Inc. formed an acquisition over Revolutionary Medical Devices, Inc. they manufacture products for smoothing the functioning of air passage inside the human body.
In September 2016, Schiller AG threw into orbit their device called touch 7. It was more efficient in detecting the problems in pulmonary functioning.
Test Types Covered:
End Users Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.